
Krakenimages.com // Shutterstock
Thyroid disorders, diabetes, and high cholesterol dominate AI healthcare visits, reflecting a shift in how Americans manage long-term health.
When patients visit an AI healthcare provider, they’re not typically seeking a diagnosis for mysterious symptoms or treatment for acute emergencies. They’re managing conditions they’ve lived with for years.
Prescription data from Doctronic, an AI telehealth platform, reveals that chronic disease management dominates AI healthcare visits. Medications for thyroid disorders, Type 2 diabetes, and high cholesterol rank among the top five most prescribed, trailing only common pain relievers.
Levothyroxine, the standard treatment for hypothyroidism, ranks as the third most prescribed medication on the platform. Metformin, the first-line treatment for Type 2 diabetes, comes in fourth. Atorvastatin, a widely used cholesterol-lowering statin, rounds out the top five.
The pattern suggests AI healthcare could be a front door for chronic disease management — conditions that require ongoing medication access rather than complex diagnostic workups. For patients living with these conditions, the appeal is straightforward: continued access to medications they’ve taken for years, without the friction of scheduling appointments weeks in advance for visits that may last only minutes.
The Chronic Disease Burden
The medications appearing at the top of the list reflect the conditions affecting the largest share of the American population — and the ones placing the greatest strain on the healthcare system.
An estimated 20 million Americans have some form of thyroid disease, according to the American Thyroid Association, with hypothyroidism being the most common. Up to 60% of those with thyroid disease are unaware of their condition, making it one of the most underdiagnosed conditions in the country. For those who have been diagnosed, treatment typically means daily levothyroxine for the rest of their lives.
Once a patient’s thyroid levels stabilize — often within the first year of treatment — many go years without needing changes to their medication. The dosage stays the same, the routine stays the same, and the only variable is maintaining prescription access. Yet many refills require a provider visit, taking up appointment slots and physician time for what amounts to a brief confirmation that nothing has changed.
Type 2 diabetes tells a similar story at an even larger scale. The condition affects roughly 38 million Americans, with the CDC noting that 90% to 95% of all diabetes cases are Type 2. Metformin has been the first-line treatment for decades, and for patients whose blo